加载中
ProKidney Corp. is a biotechnology firm currently in the clinical trial phase, specializing in the development of innovative cell-based treatments. Their flagship product is Renal Autologous Cell Therapy (RAC-T), a unique cellular admixture derived from a patient's own cells. RAC-T is undergoing significant clinical evaluation; it is concurrently in Phase III and Phase II trials for individuals with moderate to severe diabetic kidney disease. Furthermore, the company is conducting a Phase I clinical trial to assess RAC-T's potential for patients born with congenital anomalies affecting the kidneys and urinary tract. The company was established in 2015 and operates from its headquarters in Winston-Salem, North Carolina.
常规交易时段
US$1.715
−US$0.025 · -1.44%
盘中时间采用ET。市场数据可能有所延迟。
ProKidney Corp. is a biotechnology firm currently in the clinical trial phase, specializing in the development of innovative cell-based treatments. Their flagship product is Renal Autologous Cell Therapy (RAC-T), a unique cellular admixture derived from a patient's own cells. RAC-T is undergoing significant clinical evaluation; it is concurrently in Phase III and Phase II trials for individuals with moderate to severe diabetic kidney disease. Furthermore, the company is conducting a Phase I clinical trial to assess RAC-T's potential for patients born with congenital anomalies affecting the kidneys and urinary tract. The company was established in 2015 and operates from its headquarters in Winston-Salem, North Carolina.
日内区间
当前US$1.715
52周区间
当前US$1.715
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
卖出
估值
42
合理估值
情绪
52
多空交织
风险
75
高风险
动量
31
动能减弱
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
ProKidney Corp. is a biotechnology firm currently in the clinical trial phase, specializing in the development of innovative cell-based treatments. Their flagship product is Renal Autologous Cell Therapy (RAC-T), a unique cellular admixture derived from a patient's own cells. RAC-T is undergoing significant clinical evaluation; it is concurrently in Phase III and Phase II trials for individuals with moderate to severe diabetic kidney disease. Furthermore, the company is conducting a Phase I clinical trial to assess RAC-T's potential for patients born with congenital anomalies affecting the kidneys and urinary tract. The company was established in 2015 and operates from its headquarters in Winston-Salem, North Carolina.
日内区间
当前US$1.715
52周区间
当前US$1.715
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 89.3万 USD | 7.6万 USD | — | — | — |
| 毛利 | 89.3万 USD | 7.6万 USD | — | — | — |
| 研究与开发 | 1.14亿 USD | 1.28亿 USD | 1.07亿 USD | 8207万 USD | 4625.5万 USD |
| 销售、一般及管理费用 | 5177.7万 USD | 5608.4万 USD | 4481.5万 USD | 7093.7万 USD | 885.5万 USD |
| 营业费用 | 1.66亿 USD | 1.84亿 USD | 1.52亿 USD | 1.53亿 USD | 5511万 USD |
| 利息收入 | 1381.3万 USD | 1975.2万 USD | 2208.3万 USD | 598.3万 USD | 2000 USD |
| 利息支出 | 4000 USD | 9000 USD | 1.2万 USD | 21.5万 USD | — |
| 折旧和摊销 | 657.5万 USD | 543.2万 USD | 385.3万 USD | 303.6万 USD | 198.4万 USD |
| 营业利润 | −1.65亿 USD | −1.84亿 USD | −1.52亿 USD | −1.53亿 USD | −5511万 USD |
| 净利润 | −6898.6万 USD | −6118.6万 USD | −3546.8万 USD | −1.08亿 USD | −5514.6万 USD |
公司数据更新于 2026年10月12日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$4.67
上涨空间 172.30%报告持有此股票敞口的交易所交易基金。
iShares Russell 2000 ETFIWM468.12万0.01%787.4亿 USD0.19%US$278.8-0.05%
Vanguard Extended Market ETFVXF241.29万0.00%954亿 USD0.05%US$234.61-0.17%
Schwab U.S. Small-Cap ETFSCHA139.61万0.01%218.24亿 USD0.03%US$32.765-0.08%
iShares Russell 2000 Growth ETFIWO118.14万0.01%139.17亿 USD0.24%US$355.76-0.29%
Simplify Propel Opportunities ETFSURI84.17万1.11%7606.44万 USD2.82%US$17.06-0.14%
Vanguard Russell 2000 ETFVTWO81.77万0.00%180亿 USD0.06%US$112.6-0.05%
iShares Micro-Cap ETFIWC59.42万0.05%13.17亿 USD0.60%US$182.66-0.19%
iShares Russell 2000 Value ETFIWN52.68万—137.49亿 USD0.24%US$211.15+0.13%iShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFSchwab U.S. Small-Cap ETFSCHAiShares Russell 2000 Growth ETFIWOSimplify Propel Opportunities ETFSURIVanguard Russell 2000 ETFVTWOiShares Micro-Cap ETFIWCiShares Russell 2000 Value ETFIWNAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
